



Erchonia FX 635

Hands free Laser

Introducing the FX 635 from Erchonia®

Now you can relieve the pain and inflammation of the heel associated with plantar fasciitis. Our new FDA market cleared laser has been proven in clinical tests to effectively treat this painful condition. The regenerative powers of this low level laser technology can reduce inflammation and eliminate pain in the plantar fascia in only a matter of weeks and return your patients to an active life once again.

Unlike other lasers on the market, the FX 635 is proven to promote cellular regeneration through painless bio-stimulation. It provides patients experiencing chronic heel pain with a non-invasive, efficacious solution to quickly improve their walking comfort and quality of life without surgery. While other lasers may claim to treat this problem, only the FX 635 has been market cleared by the FDA to treat plantar fasciitis.

SPECIFICATIONS

- Configuration: (3) Class 2 17.25mW Line Generating Diodes
- Wavelength: 635nm
- Modulation: Variable
- Weight: 65lbs (29.48 kg)
- Height: 70in (177.8 cm) (Average – Adjustable)
- Two Independent Adjustable Arms For Desired Laser Concentration
- 4 Locking Anti-Static Casters
- Display: Full Color Touch Screen Control
- Power Source: 100-240VAC 50-60Hz
- Chassis: Powder Coated Aircraft Aluminum
- Housing & Covers: Non-Allergenic Material, Spray Finished
- Accessories: 2-Keys, Power Cord, Laser Safety Glasses
- Compliant to: ISO 13485 Medical Device Quality, IEC 60825-1 Laser Safety, IEC 60601-1-2 EMC, IEC 60601-1 Safety, CE Mark, CB Certified
- FDA Laser Class 2 / FDA Device Class II / EU Device Class IIa, Laser Class II



US PAT 6,013,096; US PAT 6,746,473; US PAT 8,439,927; US PAT 8,366,756; US PAT 8,348,985; US PAT 8,097,029; US PAT 7,922,751 Patented, US and international patents and patent pending. For more information go to www.erschonia.com.

 **LASER RADIATION**
DO NOT STARE INTO BEAM
CLASS 2 LASER
635nm 17.25 ± 1.25mW
IEC 60825-1:2001
Complies with 21 CFR 1040.10 and 1040.11
except for deviations pursuant to
Laser Notice No. 50, dated July 26, 2001



FX 635 is FDA market cleared for the treatment of chronic heel pain (plantar fasciitis)



FX 635 has just concluded level (1) trial for the treatment of chronic low back pain.



Low Back Pain

- More than 80% of the population will experience an episode of LBP, with subsequent episodes ranging from 25%-44% within one year.
- LBP is now the most common cause for disability and cause for 149 million days of work are lost annually.
- Treatments for LBP have risen almost 200% in the past two decades.
- In 2005 Americans spent \$85.9 billion looking for relief from back pain.



Low Back Pain

Not only are more people seeking treatment for back pain, but the price of treatment per person is also up. In the JAMA study, researchers at the University of Washington and Oregon Health & Science University compared national data from 3,179 adult patients who reported spine problems in 1997 to 3,187 who reported them in 2005-and found that inflation-adjusted annual medical costs increased from \$4,695 per person to \$6,096.



Treatments for LBP

- Spinal Injections
- Surgery
- Opioid Medications
- Standard therapy- PT, Chiropractic and Massage



FX 635 for Heel Pain

- Plantar Heel Pain is the most common pathologies of the foot
- Dr. Zang has developed numerous protocols for just the foot alone with the FX 635 laser.
- The first and only FDA cleared device for the treatment of Plantar fasciitis.
- Clinical manifestation of chronic Plantar Fasciitis can be disabling, and typical non surgical approaches can take months to show improvement.



Standard treatment for Plantar Fasciitis

- Splints
- Orthotic Insoles
- Foot Brace
 - None of which have been proven to be very effective and only offer temporary relief.
 - Surgery is required in some cases- Most doctors feel that non-surgical treatment should be considered for at least 6 months before opting for surgery.

Protocol

- ❖ 2 treatments a week for 3 weeks.
- ❖ Area- top of foot (Dorsal Aspect), the myofascial junction of the heel and the plantar aspect.
- ❖ All treated simultaneously. 10 minutes per area.



